Pituitary tumor enlargement in two patients with acromegaly during pegvisomant therapy

Pituitary

Volumn 10, Issue 3, 2007, Pages 283-289

  Frohman, Lawrence A ^a   Bonert, Vivien ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acromegaly; Pegvisomant; Tumor growth

Indexed keywords

ANTIMIGRAINE AGENT; GROWTH HORMONE; LEVOTHYROXINE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; ADULT; ANAMNESIS; ARTICLE; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GROWTH HORMONE BLOOD LEVEL; HEADACHE; HUMAN; HYPOPHYSIS TUMOR; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TRANSSPHENOIDAL SURGERY; TUMOR GROWTH; TUMOR VOLUME;

ACROMEGALY; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; OCTREOTIDE; PITUITARY NEOPLASMS;

EID: 35848944677     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-007-0042-x     Document Type: Article

References (11)

1. Newman CB (1999) Medical therapy for acromegaly. Med Clin North Am 28:171-190
2. Freda PU (2004) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013-3018
3. Van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L et al (2001) Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759
4. Van der Lely AJ, Muller AJ, Janssen JA, Davis RJ, Zib KA, Scarlett JA et al (2001) Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient. J Clin Endocrinol Metab 86:478-481
5. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F et al (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: Effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477
6. Di Chiro G, Nelson KB (1962) The volume of the sella turcica. Am J Roentgenol Radium Ther Nucl Med 87:989-1008
7. Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A et al (2007) Rapid pituitary tumor shrinkage with dissociation between anti-proliferative and anti-secretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab e-pub Feb 20, 2007
8. Bevan JS (2005) The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856-1863
9. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V et al (2005) A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 90:4405-4410
10. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A et al (1992) Octreotide treatment of acromegaly: A randomized, multicenter study. Ann Intern Med 117:711-718
11. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, Van der Lely AJ et al (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177